dc.contributor.author | ABOU JOKH CASAS, ESTEPHANY | |
dc.contributor.author | Pubul Nuñez, Virginia | |
dc.contributor.author | Anido Herranz, Urbano | |
dc.contributor.author | Mallón Araujo, María del Carmen | |
dc.contributor.author | Del Pombo Pasín, Maria Carmen | |
dc.contributor.author | Garrido Pumar, Miguel | |
dc.contributor.author | Cabezas Agrícola, José Manuel | |
dc.contributor.author | Cameselle Teijeiro, Jose Manuel | |
dc.contributor.author | Hilal, A. | |
dc.contributor.author | Ruibal Morell, Alvaro | |
dc.date.accessioned | 2022-04-12T11:37:28Z | |
dc.date.available | 2022-04-12T11:37:28Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1007-9327 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32308351 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16456 | |
dc.description.abstract | BACKGROUND: (177)Lu peptide receptor radionuclide therapy (PRRT) is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine tumors. AIM: To determine the impact of PRRT on quality of life, radiologic and metabolic response, overall survival, prognostic factors and toxicity. METHODS: Thirty-six patients treated with (177)Lu-PRRT from 2016 to 2019 were included. The most frequent location of the primary tumor was the gastrointestinal tract (52.8%), pancreas (27.8%), and nongastropancreatic neuroendocrine tumor (11.1%). The liver was the most common site of metastasis (91.7%), followed by distant nodes (50.0%), bone (27.8%), peritoneum (25.0%) and lung (11.1%). Toxicity was evaluated after the administration of each dose. Treatment efficacy was evaluated by two parameters: stable disease and disease progression in response evaluation criteria in solid tumors 1.1 criterion and prognostic factors were tested. RESULTS: From 36 patients, 55.6% were men, with a median age of 61.1 +/- 11.8 years. Regarding previous treatments, 55.6% of patients underwent surgery of the primary tumor, 100% of patients were treated with long-acting somatostatin analogues, 66.7% of patients were treated with everolimus, 27.8% of patients were treated with tyrosine kinase inhibitor, and 27.8% of patients were treated with interferon. One patient received radioembolization, three patients received chemoembolization, six patients received chemotherapy. Hematological toxicity was registered in 14 patients (G1-G2: 55.5% and G3: 3.1%). Other events presented were intestinal suboclusion in 4 cases, cholestasis in 2 cases and carcinoid crisis in 1 case. The median follow-up time was 3 years. Currently, 24 patients completed treatment. Nineteen are alive with stable disease, two have disease progression, eight have died, and nine are still receiving treatment. The median overall survival was 12.5 mo (95% confidence interval range: 9.8-15.2), being inversely proportional to toxicity in previous treatments (P < 0.02), tumor grade (P < 0.01) and the presence of bone lesions (P = 0.009) and directly proportional with matching lesion findings between Octreoscan and computed tomography pre-PRRT (P < 0.01), , primary tumor surgery (P = 0.03) and metastasis surgery (P = 0.045). In a multivariate Cox regression analysis, a high Ki67 index (P = 0.003), a mismatch in the lesion findings between Octreoscan and computed tomography pre-PRRT (P < 0.01) and a preceding toxicity in previous treatments (P < 0.05) were risk factors to overall survival. CONCLUSION: Overall survival was inversely proportional to previous toxicity, tumor grade and the presence of bone metastasis and directly proportional to matching lesion findings between Octreoscan and computed tomography pre-PRRT and primary tumor and metastasis surgery. | en |
dc.rights | Atribución-NoComercial 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject.mesh | Intestinal Neoplasms | * |
dc.subject.mesh | Stomach Neoplasms | * |
dc.subject.mesh | Proportional Hazards Models | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Neoplasm Metastasis | * |
dc.subject.mesh | Neoplasm Grading | * |
dc.subject.mesh | Octreotide | * |
dc.subject.mesh | Survival Rate | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Neuroendocrine Tumors | * |
dc.subject.mesh | Pancreatic Neoplasms | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Prognosis | * |
dc.title | Evaluation of Lu-177-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors | en |
dc.type | Journal Article | es |
dc.authorsophos | Abou Jokh Casas, E.;Pubul Núñez, V.;Anido-Herranz, U.;Del Carmen Mallón Araujo, M.;Del Carmen Pombo Pasín, M.;Garrido Pumar, M.;Cabezas Agrícola, J. M.;Cameselle-Teijeiro, J. M.;Hilal, A.;Ruibal Morell, Á | |
dc.identifier.doi | 10.3748/wjg.v26.i13.1513 | |
dc.identifier.pmid | 32308351 | |
dc.identifier.sophos | 38889 | |
dc.issue.number | 13 | es |
dc.journal.title | WORLD JOURNAL OF GASTROENTEROLOGY | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Anatomía Patolóxica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Endocrinoloxía | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Medicina nuclear | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médica | es |
dc.page.initial | 1513 | es |
dc.page.final | 1524 - | es |
dc.rights.accessRights | openAccess | |
dc.subject.decs | pronóstico | * |
dc.subject.decs | resultado del tratamiento | * |
dc.subject.decs | neoplasias gástricas | * |
dc.subject.decs | tasa de supervivencia | * |
dc.subject.decs | neoplasias intestinales | * |
dc.subject.decs | tumores neuroendocrinos | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | neoplasias pancreáticas | * |
dc.subject.decs | metástasis neoplásica | * |
dc.subject.decs | anciano | * |
dc.subject.decs | octreótido | * |
dc.subject.decs | humanos | * |
dc.subject.decs | gradación neoplásica | * |
dc.subject.decs | modelos de riesgos proporcionales | * |
dc.subject.keyword | CHUS | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 26 | es |